162 related articles for article (PubMed ID: 24991162)
1. Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial.
Zhu M; Xiao S; Li G; Li X; Tang M; Yang S; Xu X; Feng L; Liu K; Hu L
Shanghai Arch Psychiatry; 2013 Aug; 25(4):244-53. PubMed ID: 24991162
[TBL] [Abstract][Full Text] [Related]
2. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
3. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
4. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
5. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
6. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
[TBL] [Abstract][Full Text] [Related]
7. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
8. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
10. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial.
Annweiler C; Fantino B; Parot-Schinkel E; Thiery S; Gautier J; Beauchet O
Trials; 2011 Oct; 12():230. PubMed ID: 22014101
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
Zhang N; Wei C; Du H; Shi FD; Cheng Y
Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
14. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
15. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
16. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
Wilcock G; Möbius HJ; Stöffler A;
Int Clin Psychopharmacol; 2002 Nov; 17(6):297-305. PubMed ID: 12409683
[TBL] [Abstract][Full Text] [Related]
18. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Orgogozo JM; Rigaud AS; Stöffler A; Möbius HJ; Forette F
Stroke; 2002 Jul; 33(7):1834-9. PubMed ID: 12105362
[TBL] [Abstract][Full Text] [Related]
20. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
Schneider LS; Dagerman KS; Higgins JP; McShane R
Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
